Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Abroad (travel likely)RecruitingPHASE2

Conditions

Non-Hodgkin Lymphoma · Burkitt Lymphoma · Diffuse Large B-Cell Lymphoma · Primary Mediastinal B-cell Lymphoma · CD20+ Lymphoblastic Lymphoma · Follicular Lymphoma, Grade III

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

New York Medical College, Valhalla, New York, United States
Contact: Study coordinator (Jessica Hochberg, MD) · jessica_hochberg@nymc.edu · 914-594-2150
Contact: Study coordinator (Mitchell Cairo, MD) · mitchell_cairo@nymc.edu · 914-594-2150

Study leads

Mitchell Cairo, MD
Study Chair
New York Medical College

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

Follicular Lymphoma · Lymphoma

Abroad (travel likely)RecruitingPHASE2

Washington D.C., United States · Basking Ridge, United States

SynKIR-310 for Relapsed/Refractory B-NHL

B Cell Lymphoma · NHL, Adult · Mantle Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1

Denver, United States · Atlanta, United States

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

B-NHL · B-Non Hodgkin Lymphoma · Acute Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Diffuse Large Cell Lymphoma · Non-Hodgkin Lymphoma · Burkitt Lymphoma

Abroad (travel likely)RecruitingPHASE1

Bethesda, United States